[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial]

What Was Tested

The paper reports a study of Cerebrolysin, published as a randomized controlled trial.

To evaluate the effects of Cerebrolysin on brain microstructural integrity and blood-brain barrier (BBB) permeability, as well as their longitudinal changes, using diffusion tensor imaging (DTI) and perfusion computed tomography (PCT) in patients with acute ischemic stroke (AIS).

Mixed-effects linear regression models accounting for repeated measures were used to evaluate treatment effects over time, incorporating clinical and imaging predictors, timepoints, and interaction terms.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Cerebrolysin group and the comparison group should start out alike.

The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.

Brain imaging was performed at 24 hours and on day 14 post-IVT.

DTI metrics included axial diffusivity (AD), radial diffusivity (RD), mean diffusivity (MD; 10-6 mm²/s), and fractional anisotropy (FA; ·10-4) assessed within the infarct core and contralateral region.

Infarct volume (mL) was determined by diffusion-weighted imaging at 24 hours and by non-contrast CT on day 14.

What Was Measured

The subject headings attached to it are Ischemic Stroke, Blood-Brain Barrier, Diffusion Tensor Imaging, Amino Acids, Neuroprotective Agents, Brain and Thrombolytic Therapy.

Author keywords: Cerebrolysin, blood–brain barrier permeability, diffusion tensor MRI and intravenous thrombolysis.

What This Means in Plain Language

The paper is a randomized study of Cerebrolysin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova), a journal based in Russia (Federation).

More context: the Cerebrolysin compound page, all human trials.